eGFR is estimated from creatinine, which your muscles make, so a marathoner and a frail person with the same kidneys get very different numbers 1. The 2009 formula patched this by multiplying the result by 1.159 for Black patients, on an unvalidated theory about muscle mass 2. Cystatin C is the cleaner marker: every cell makes it at a near-constant rate, so it barely cares whether you're frail or jacked. Run with creatinine, the combined formula lands within 30% of true function 92% of the time, versus 87% for creatinine alone 3.
The race-free formula would newly identify about 434,000 Black adults with previously missed kidney disease 4. On the transplant list, 27% of Black candidates moved into a higher-priority stage, worth roughly 5.3 more transplants per 1,000 5. Cystatin C reaches everyone: when the two markers disagree and cystatin C reads much lower, that gap alone predicts a death rate about 70% higher, a hazard on the order of being a current smoker 6.
Who this is for. Anyone whose muscle is unusual for their age — the frail and cirrhotic, or the bodybuilders and creatine users. Anyone Black whose recent creatinine eGFR came back between 50 and 70. Anyone facing a decision the number drives. Healthy, with an eGFR above 60? Skip it.
What the number buys. Within a week your charted kidney figure is the most accurate you've had, and for most people nothing changes. For the person carrying hidden disease, the next visit adds a nephrology referral and, if diabetes is in play, an SGLT2 inhibitor; caught before symptoms, the first ninety days are where the trajectory bends. For the person about to take a kidney-stressing drug, the dose is set from a true number, and the acute injury never happens 7.
The fine print — when to skip it, and what people get wrong
When cystatin C also misleads: active infection, an autoimmune flare, recent surgery, oral or IV steroids, and untreated hyperthyroidism all raise it without harming the kidneys 8. Wait until you're back at baseline, or trust the creatinine instead.
"Dropping race hurts Black patients." The reverse — it reveals hidden disease and shortens transplant waits 5. Living-donor evaluation is the one exception it wasn't built for.
"Cystatin C replaces creatinine." No — the combined formula beats either alone, which is why KDIGO recommends both 9.
- 1Shlipak MG, Inker LA, Coresh J (2022). Serum Cystatin C for Estimation of GFR. JAMA. link
- 2Delgado C, Baweja M, Crews DC, et al. (2022). A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. American Journal of Kidney Diseases. link
- 3Inker LA, Eneanya ND, Coresh J, et al. (2021). New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. New England Journal of Medicine. link
- 4Diao JA, Wu GJ, Taylor HA, et al. (2021). Clinical Implications of Removing Race From Estimates of Kidney Function. JAMA. link
- 5Mohottige D, Boulware LE, Diao JA, et al. (2024). Removing race from kidney function algorithm impact on Black candidates for kidney transplantation. JAMA Internal Medicine. link
- 6Estrella MM, Carrero JJ, Inker LA, et al. (2025). Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis. JAMA. link
- 7Davis JD, Olsen MA, Bommelaere C, et al. (2020). Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. link
- 8Chen TK, Knicely DH, Grams ME (2022). Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR. Kidney360. link
- 9KDIGO (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. link
დაკავშირებული სახელმძღვანელოში (9)
- — This is the number that stages early kidney disease — get it right and you catch CKD in the window that matters.
- — Your eGFR feeds straight into the PREVENT heart-risk score; a race-free, cystatin-C reading keeps that estimate honest.
- — Creatine supplements inflate the creatinine your eGFR is built on; cystatin C reads through the artefact.
- — Just as diabetes is screened in the eye each year, the kidney gets watched with eGFR and cystatin C.
- — Same lesson, different lab: a single standard number can mislead in specific people. Know when your eGFR, like your HbA1c, needs a second marker.
- — A reassuring eGFR can hide real disease — exactly the 'normal isn't the same as fine' problem.
- — Another everyday medical tool that was quietly less accurate for some patients — same lesson about not trusting a single number blindly.
- — Same skill on a different organ: knowing what your kidney numbers actually mean and their limits.
- — Your eGFR is the number that decides if this swap is safe or dangerous — bad kidneys can't clear the extra potassium.
Race-Free eGFR and Cystatin C
Direct-pay range $50–$130 for cystatin C with eGFR bundled (Quest 94588, LabCorp 121265); often covered by insurance under medical-necessity codes including Medicare LCD L37618. Trivial relative to the downstream drug/transplant decisions it informs.
A one-time ask: verify the lab uses CKD-EPI 2021 and request cystatin C at a relevant decision-point. Single conversation with a clinician; no ongoing behaviour change.
Landmark NEJM development paper (Inker et al. 2021) plus NKF-ASN Task Force final report (Delgado et al. AJKD 2022) plus KDIGO 2024 grade-1B recommendation plus CKD Prognosis Consortium meta-analysis of 821,327 outpatients (Estrella et al. JAMA 2025). Multiple large cohorts, guideline alignment across NKF, ASN, KDIGO, KDOQI, CAP.
Earlier and more accurate CKD diagnosis enables earlier RAS-inhibitor and SGLT2-inhibitor initiation in the patients who need them — chiefly Black patients previously masked by the 2009 equation and sarcopenic/cirrhotic patients with hidden CKD on creatinine alone. The CKD-PC meta-analysis of 821k outpatients also showed eGFRdiff itself carries an HR of 1.69 for all-cause mortality, independent of single-marker GFR (Estrella et al., JAMA 2025). Disease-prevention magnitude is meaningful but bounded — gains accrue to subpopulations near decision thresholds, not the general adult.
Right-sized drug dosing — chemotherapy, contrast, SGLT2 inhibitors, narrow-therapeutic-index antibiotics — reduces nephrotoxicity events and AKI in the weeks after a kidney-function-driven decision. Real but limited to patients near a clinical decision-point; most readers won't feel a daily change. (Casal et al., Kidney360 2022; Davis et al., Radiology 2020.)